CloudBlue and CloudSense Strike a Strategic Relationship to Connect Telecommunications Providers With a Broad Ecosystem of ICT Channel Partners via a New Digital Catalog
5.4.2022 16:00:00 EEST | Business Wire | Press release
CloudBlue, a leading cloud ecosystem technology company which powers some of the largest commerce platforms for cloud and IT channel products globally, today announced an agreement with CloudSense, provider of one of the market’s most powerful Configure, Price, Quote (CPQ) platforms.
CloudSense has a well-established footprint within the telecommunications industry, with customers including prominent regional and international brands such as BT, Starhub and Vodafone Ziggo. By providing a direct integration from CloudBlue Connect™ to the CloudSense CPQ platform, CloudSense’s community of telecommunications customers will be able to tap into a new pool of ICT offerings and scale their business faster than ever.
The direct integration between CloudBlue Connect and CloudSense CPQ will allow telecommunications providers to enrich their own portfolio of B2B solutions more efficiently. This new integration will streamline their ability to procure traditional ICT services and bundle them into a wide range of innovative B2B XaaS solutions, which can be sold by a direct sales force or a network of resellers. Telecommunications and ICT providers will be able to create simple and easy quotes and contracts via CloudSense CPQ without the need to rekey orders or engage in manual processes.
CloudBlue will benefit from this new relationship through expanded exposure of its 200+ XaaS digital solutions to the telecommunications community. The initiative clears the way for CloudSense’s customers to access the tools they need to provide businesses of all sizes with the anything-as-a-service (XaaS) offerings that have surged in demand post-pandemic.
“As telcos look for new ways to diversify their offerings, cross-platform integration becomes key to providing end-users the best in Cloud. CloudBlue’s new agreement with CloudSense marks the latest in a series of innovative and creative relationships forming across Cloud to the continued delight of channel partners,” said Tarik Faouzi, senior vice president of CloudBlue.
“CloudSense recognizes the importance of bringing to market innovative solutions that address challenges in our focus verticals. We believe the CloudSense-CloudBlue agreement establishes the first Marketplace of its kind to facilitate commercial innovation across the communications ecosystem. This will give communications service providers broader access to a global network of channel partners and remove the need for manual input when drafting quotes and contracts,” said Jonathan English, CEO, CloudSense.
About CloudSense
The CloudSense Configure, Price, Quote (CPQ) application suite powers increased productivity and profits for ambitious enterprises allowing them to launch faster, sell more and fulfill orders faultlessly. Its growing global community of customers rely on CloudSense to deliver sales transformation within the Communications and Media industries. Leading brands including Telefonica, Telstra, and Informa use CloudSense's portfolio of applications to streamline the entire customer lifecycle, providing a better customer experience while improving business performance. To find out more, visit CloudSense.com
About CloudBlue
CloudBlue helps businesses succeed in the as-a-service economy and accelerate time to revenue by managing subscription and billing, vendor and product information, and partner onboarding across multiple channels. Through its leading ecosystem orchestration platform, CloudBlue enables companies to create their own ecosystems, as well as connect vendor and go-to-market ecosystems, automating the distribution of traditional and digital products and services across partners in the digital supply chain. CloudBlue serves more than 180 companies around the globe and powers the world’s largest cloud B2B marketplaces, which represent 30 million B2B cloud subscriptions. Learn more about CloudBlue at www.cloudblue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005045/en/
Contact information
Andrew Zelinko
CloudBlue
Andrew.Zelinko@cloudblue.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom